In-Depth Analysis of the Plasma Proteome in ME/CFS Exposes Disrupted Ephrin-Eph and Immune System Signaling.
Germain, Arnaud, Levine, Susan M, Hanson, Maureen R · Proteomes · 2021 · DOI
Quick Summary
Researchers measured 4,790 different proteins in the blood of 20 ME/CFS patients and 20 healthy people to look for differences that might explain the disease. They found that 19 proteins were significantly different between the two groups, particularly involving pathways related to immune function and cell communication. Using these protein patterns, they were able to distinguish ME/CFS patients from healthy controls with high accuracy, suggesting proteins in blood could potentially help diagnose ME/CFS.
Why It Matters
ME/CFS currently lacks objective biomarkers for diagnosis, relying entirely on symptom-based criteria. This study identifies candidate blood proteins that could form the basis for a diagnostic test and reveals specific biological pathways disrupted in ME/CFS, potentially pointing toward future treatment targets. Understanding the molecular basis of the disease is essential for developing therapies beyond symptom management.
Observed Findings
Nineteen proteins showed significant differential abundance between ME/CFS patients and controls (p<0.05)
Pathway analysis robustly highlighted the ephrin-Eph signaling pathway, which regulates cell-cell communication and immune response
Individual proteins achieved ROC-AUC values >0.85 for distinguishing ME/CFS from controls; protein ratios achieved AUC values up to 0.95
Protein alterations implicated extracellular matrix, immune system, and cell-cell communication pathways
The study measured proteins across a nine-log dynamic range, detecting both highly abundant and rare proteins
Inferred Conclusions
Plasma proteomics can distinguish ME/CFS patients from healthy controls with high accuracy, suggesting potential diagnostic utility
Ephrin-Eph signaling pathway disruption may be a key molecular feature of ME/CFS pathophysiology
Protein pairs with established biological relationships show particularly strong discriminatory power, implying the identified differences reflect coherent biological dysfunction
Plasma biomarkers may provide objective tools for both diagnosing ME/CFS and understanding its molecular basis
Remaining Questions
Do these proteomic signatures differ by ME/CFS severity, disease duration, or patient subtype?
What This Study Does Not Prove
This pilot study does not prove that the identified proteins cause ME/CFS or that measuring them would be practical for routine clinical diagnosis—findings must be validated in larger, more diverse cohorts. The study design cannot establish whether proteomic changes are primary disease drivers or secondary consequences of illness. The study is limited to females and cannot confirm whether findings generalize to male ME/CFS patients.